Provided by Tiger Fintech (Singapore) Pte. Ltd.

Entrada Therapeutics, Inc.

8.11
-0.2100-2.52%
Post-market: 8.110.00000.00%18:26 EDT
Volume:77.67K
Turnover:634.44K
Market Cap:307.80M
PE:13.37
High:8.47
Open:8.47
Low:8.10
Close:8.32
Loading ...

Entrada Therapeutics Inc. Unveils Corporate Presentation Highlighting Clinical Advancements and Strategic Focus on Intracellular Therapeutics

Reuters
·
04 Jun

Entrada Therapeutics Appoints Dr. Maha Radhakrishnan to Board of Directors Amidst Clinical Advancements in Duchenne Therapies

Reuters
·
03 Jun

Entrada Therapeutics Appoints Maha Radhakrishnan, M.d., to Its Board of Directors

THOMSON REUTERS
·
03 Jun

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule

Reuters
·
03 Jun

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
03 Jun

Entrada Therapeutics Company on Track to Begin Elevate-45-201 in Q3 2025

THOMSON REUTERS
·
28 May

Entrada Therapeutics Announces EU Authorization to Initiate Phase 1/2 Clinical Study of ENTR-601-45 for Duchenne Muscular Dystrophy

Reuters
·
28 May

Entrada Therapeutics Receives Authorization in the European Union to Initiate Elevate-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of Entr-601-45 in Patients Living With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

THOMSON REUTERS
·
28 May

Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital

TIPRANKS
·
12 May

Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Qiagen (QGEN)

TIPRANKS
·
12 May

Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating

TIPRANKS
·
09 May

Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Galmed Pharmaceuticals (GLMD) and Xilio Therapeutics (XLO)

TIPRANKS
·
09 May

Entrada Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

Entrada Therapeutics Inc: Cash Runway Expected Into Q2 2027 With $383 Mln in Cash

THOMSON REUTERS
·
08 May

Entrada Therapeutics Inc expected to post a loss of 79 cents a share - Earnings Preview

Reuters
·
05 May

North American Morning Briefing: Stock Futures Down As Oil Plunges

Dow Jones
·
05 May

Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Zacks
·
01 May

BRIEF-Entrada Therapeutics Inc - Approves Strategic Plan Focusing On DMD Programs - SEC Filing

Reuters
·
30 Apr

Entrada Therapeutics Inc - Expects Cash Runway to Extend Into Q2 2027 - SEC Filing

THOMSON REUTERS
·
30 Apr

Entrada Therapeutics Inc - to Reduce Workforce by Approximately 20% Under New Plan - SEC Filing

THOMSON REUTERS
·
30 Apr